Report of Foreign Issuer (6-k)
February 03 2016 - 7:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2016
Commission File Number: 001-36596
___________________
TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)
96 Skyway Avenue
Toronto, Ontario M9W 4Y9
Canada
(Address of principal executive offices)
___________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form
40-F [X]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[ ]
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Trillium Therapeutics Inc. |
|
|
|
|
Date: February 3, 2016 |
|
|
By: /s/ James
Parsons
|
|
Name: James Parsons |
|
Title: Chief Financial Officer
|
2
EXHIBIT INDEX
FOR IMMEDIATE RELEASE |
NASDAQ:TRIL |
|
TSX: TR |
TRILLIUM THERAPEUTICS DOSES FIRST PATIENT WITH TTI-621, A
NOVEL IMMUNE CHECKPOINT INHIBITOR TARGETING CD47
Toronto, Canada February 3, 2016 Trillium
Therapeutics Inc. (NASDAQ: TRIL; TSX: TR) a clinical stage immuno-oncology
company developing innovative therapies for the treatment of cancer, today
announced that it has initiated dosing in its Phase 1 clinical trial of TTI-621
(SIRPaFc), a novel checkpoint inhibitor of the innate immune system, in relapsed
or refractory hematologic malignancies.
TTI-621 is an antibody-like fusion protein that blocks the
inhibitory activity of CD47, a molecule that is overexpressed by a wide variety
of tumors. CD47 binds to SIRPa on macrophages and delivers a do not eat signal
that inhibits the ability of macrophages to engulf and destroy cancer cells.
Preclinical studies have shown that TTI-621 has anti-tumor activity
across a range of hematologic tumors.
This is an exciting time for Trillium as we now emerge as a
clinical stage oncology company evaluating a novel immune checkpoint inhibitor,
commented Dr. Eric Sievers, Trilliums Chief Medical Officer. At a fundamental
level, a cancer patient's ineffective immune response allows the tumor to
propagate unchecked. By blocking CD47, a key cell-surface protein that inhibits
phagocytosis, we hope to summon a durable anti-tumor response in patients who
are beset by cancer.
The two-part clinical trial is designed as a multi-center,
open-label Phase 1a/1b trial, evaluating TTI-621 as a single-agent in patients
with relapsed or refractory hematologic malignancies. During the dose escalation
phase set to enroll up to 36 subjects, the safety, tolerability,
pharmacokinetics and pharmacodynamics will be characterized to determine the
optimal dose for subsequent enrollment in the expansion phase. In this second
part of the trial, the safety and preliminary antitumor activity of TTI-621 at
the optimal dose identified in the escalation phase will be explored in 1215
subjects per hematologic malignancy type: indolent B-cell lymphoma, aggressive
B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia,
multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome.
Trillium has proposed five trial sites including the Mayo
Clinic, Columbia University Medical Center, City of Hope National Medical
Center, The Colorado Blood Cancer Institute, and Tennessee Oncology.
About Trillium Therapeutics:
Trillium Therapeutics Inc. is a clinical stage immuno-oncology
company developing innovative therapies for the treatment of cancer. The
Companys lead program is a SIRPaFc antibody-like fusion protein that consists
of the CD47-binding domain of human SIRPa linked to the Fc region of a human
immunoglobulin. It is designed to act as a soluble decoy receptor, preventing
CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the
inhibitory CD47 signal enables the activation of macrophage anti-tumor effects
by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing.
Trillium also has a proprietary medicinal chemistry platform, using unique
fluorine chemistry, which permits the creation of new chemical entities from
validated drugs and drug candidates with improved pharmacological properties.
Stemming from this platform, the Companys most advanced preclinical program is
an orally-available bromodomain inhibitor, followed by an epidermal
growth factor receptor antagonist with increased uptake in the brain, both of
which have been differentiated from competitors and have potential for
best-in-class status. In addition, a number of compounds directed at undisclosed
immuno-oncology targets are currently in the discovery phase.
Caution Regarding Forward-Looking Information:
This press release may contain forward-looking statements,
which reflect Trilliums current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Such risks and uncertainties, including our expectations about the
enrollment in the Phase 1a dose escalation and expansion into Phase 1b of the
study of TTI-621, are described in the Companys ongoing quarterly and annual
reporting. Except as required by applicable securities laws, Trillium undertakes
no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of the TSX) accepts responsibility for the adequacy
or accuracy of this release.
Contact:
Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
+1 416 595 0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
-2-
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2023 to Apr 2024